Novo Nordisk slashes Wegovy prices through direct-to-consumer pharmacy

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight loss product Wegovy at a significantly reduced cost. The drugmaker has named its new program NovoCare® Pharmacy, which will sell all dose strengths of Wegovy at $499...